Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 [Yahoo! Finance]
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma (STRO) had its price target raised by Citizens Jmp from $23.00 to $35.00. They now have a "market outperform" rating on the stock.
Sutro Biopharma (STRO) had its "outperform" rating reaffirmed by Citigroup Inc..
Sutro Biopharma (STRO) is now covered by Leerink Partners. They set an "outperform" rating and a $38.00 price target on the stock.